Independent and Cooperative Roles of Adaptor Molecules in Proximal Signaling during FcεRI-Mediated Mast Cell Activation

Taku Kambayashi,1,2* Mariko Okumura,1,2 Rebecca G. Baker,1 Chih-Jung Hsu,3 Tobias Baumgart,3 Weiguo Zhang,4 and Gary A. Koretzky1,5*

A Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania1; Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania1; Department of Chemistry, University of Pennsylvania2; Department of Immunology, Duke University Medical Center, Durham, North Carolina3; and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania5

Received 17 March 2010/Returned for modification 5 April 2010/Accepted 16 June 2010

Activation through FcεRI, a high-affinity IgE-binding receptor, is critical for mast cell function during allergy. The formation of a multimolecular proximal signaling complex nucleated by the adaptor molecules SLP-76 and LAT1 is required for activation through this receptor. Based on previous T-cell studies, current dogma dictates that LAT1 is required for plasma membrane recruitment and function of SLP-76. Unexpectedly, we found that the recruitment and phosphorylation of SLP-76 were preserved in LAT1−/− mast cells and that SLP-76−/− and LAT1−/− mast cells harbored distinct functional and biochemical defects. The LAT1-like molecule LAT2 was responsible for the preserved membrane localization and phosphorylation of SLP-76 in LAT1−/− mast cells. Although LAT2 supported SLP-76 phosphorylation and recruitment to the plasma membrane, LAT2 only partially compensated for LAT1-mediated cell signaling due to its decreased ability to stabilize interactions with phospholipase Cγ (PLCγ). Comparison of SLP-76−/− LAT1−/− and SLP-76−/− LAT2−/− mast cells revealed that some functions of LAT1 could occur independently of SLP-76. We propose that while SLP-76 and LAT1 depend on each other for many of their functions, LAT2/SLP-76 interactions and SLP-76-independent LAT1 functions also mediate a positive signaling pathway downstream of FcεRI in mast cells.

Mast cell activation during allergic inflammation is mediated by the high-affinity immunoglobulin E (IgE)-binding receptor FcεRI. Cross-linking of FcεRI on mast cells by IgE/cognate antigen complexes results in the rapid release of a wide array of inflammatory mediators, including vasoactive amines and cytokines/chemokines that give rise to allergic symptoms, ranging in severity from simple urticaria to anaphylactic shock and death (14). As allergy affects ~30% of the population in developed countries (13), much attention has been placed on studying the signal transduction mechanisms involved in mast cell activation downstream of FcεRI in hopes of finding novel targets for therapeutic intervention.

Signal transduction downstream of FcεRI is initiated by the phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) contained in the signaling components (β and γ chains) of the FcεRI complex (30, 37). Once phosphorylated, these chains serve as docking sites for several protein tyrosine kinases (PTKs), including Lyn and spleen tyrosine kinase (Syk) (9, 19, 34). Recruitment of Syk to the membrane by FcεRI results in the phosphorylation of scaffold proteins known as adaptor molecules. Adaptor proteins lack enzymatic activity but instead contain protein-binding domains that are critical for the formation of a multimolecular complex, which orchestrates downstream signaling in a temporal and spatial manner. The adaptor molecules Src homology 2 (SH2) domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76) and linker of activated T cells 1 (LAT1) organize the assembly of a proximal signaling complex downstream of FcεRI. Failure to form this complex is detrimental to FcεRI-mediated mast cell function, as demonstrated by the finding that both SLP-76-deficient (22, 29, 41) and LAT1-deficient (25, 31, 32) mast cells display severely diminished degranulation and cytokine/chemokine production following FcεRI ligation. Similar proximal signaling complexes are formed downstream of several different ITAM-containing receptors. Much of our understanding of the role of adaptor molecules in signal transduction has come from identification of phosphoproteins during T-cell receptor (TCR)-mediated activation of the human Jurkat T-cell line (1, 33). These studies eventually led to a paradigm describing the sequence of events in the formation of the SLP-76/LAT1 signaling complex. According to this model, SLP-76 is found constitutively bound to Grb2-related adaptor downstream of Shc (GADS) (24) and resides in the cytosol. Upon TCR activation, the tyrosines of membrane-resident LAT1 are phosphorylated and become attachment sites for proteins such as phospholipase Cγ (PLCγ) and GADS (43, 45). SLP-76 is drawn to the membrane through a GADS/LAT1 interaction, which then permits Syk family PTKs to maximally phosphorylate the N-terminal tyrosines of SLP-76 (5, 10). Several lines of evidence support this model whereby a LAT1/SLP-76 module organizes TCR signaling. First, both

* Corresponding author. Mailing address for Gary A. Koretzky: Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III, Room 415, 421 Curie Boulevard, Philadelphia, PA 19104-6100. Phone: (215) 746-5522. Fax: (215) 746-5525. E-mail: koretzky@mail.med.upenn.edu. Published ahead of print on 6 July 2010.

** Corresponding author. Mailing address for Taku Kambayashi: Department of Pathology and Laboratory Medicine, University of Pennsylvania, 288 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6160. Phone: (215) 746-7610. Fax: (215) 573-9261. E-mail: taku.kambayashi@uphs.upenn.edu.
SLP-76- and LAT1-deficient Jurkat T cells display similar biochemical defects, such as diminished PLCγ and extracellular signal-regulated kinase (ERK) activation (10, 42). Second, T cells in SLP-76−/− and LAT1−/− mice are blocked at the same stage of development (7, 44). Third, SLP-76 can be coimmunoprecipitated with LAT1 but not with LAT1 harboring tyrosine-to-phenylalanine mutations (45). Finally, expression of a fusion protein comprised of the membrane-localizing domain of LAT1 and SLP-76 that forces localization of SLP-76 to the plasma membrane rescues the TCR-induced functional defects of both SLP-76−/− and LAT1-deficient Jurkat T cells (3). This model implies a mutually dependent relationship between SLP-76 and LAT1, where SLP-76 and LAT1 rely on each other to carry out their roles.

One might suspect that this model for LAT1/SLP-76 function would operate in all other cells that utilize these adaptor molecules for ITAM-containing receptor-mediated signaling. However, the published defects of LAT1-deficient mast cells in FcεRI-mediated signaling appeared milder than those of SLP-76−/− mast cells, although a direct comparison has never been reported. In the present study, we show that LAT1-deficient mast cells display distinct functional and biochemical defects compared to SLP-76-deficient mast cells, implying that unlike in T cells, SLP-76 may not depend entirely on LAT1 for its function in mast cells. Surprisingly, the membrane recruitment and phosphorylation of SLP-76 were also preserved in LAT1−/− mast cells. We show that LAT2 (also known as non-T-cell activation linker [NTAL] or linker for activation of B cells [LAB]), which is not expressed in naive T cells but is expressed in mast cells (15), is responsible for phosphorylation and plasma membrane recruitment of SLP-76 in the absence of LAT1. However, LAT2 cannot support all LAT1/SLP-76-associated functions, such as sustained Ca2+ flux, likely due to decreased stability of the LAT2/SLP-76/PLCγ complex. Comparison of SLP-76−/− LAT1−/− and SLP-76−/− LAT1−/− mast cells also revealed that some functions of LAT1 could occur independently of SLP-76. We propose that although SLP-76 and LAT1 are interdependent for many of their functions, LAT2/SLP-76 interactions and SLP-76-independent LAT1 functions mediate positive signaling downstream of FcεRI in mast cells.

**MATERIALS AND METHODS**

Mice. SLP-76−/−, LAT2−/−, and LAT1−/− mice have previously been described (7, 47). LAT1−/− LAT2−/− and SLP-76−/− LAT1−/− mice were obtained by breeding LAT2−/− or SLP-76−/− LAT1−/− mice, followed by interbreeding of LAT2−/− or SLP-76−/− LAT1−/− mice, respectively. Because of the rare occurrence of adult SLP-76−/− LAT1−/− mice due to perinatal lethality, SLP-76−/− LAT1−/− mast cells were also obtained from mice expressing the tamoxifen-inducible Cre recombinase (T2-Cre) and the SLP-76 exon 2 flanked with lox sites (SLP-76fl) (26). SLP-76−/− LAT1−/−, SLP−/− LAT1−/−, SLP−/− LAT1−/−, and SLP−/− LAT1−/− mice expressing T2-Cre and a Cre-inducible ROSA26 promoter-driven yellow fluorescent protein (YFP) reporter gene were treated orally with tamoxifen for 5 days to induce deletion of the gene encoding SLP-76. Mast cells were generated from the bone marrow (BM) of these mice and later sorted for YFP positivity as a marker for successful Cre recombinase induction and gene deletion. Deletion of SLP-76 protein was confirmed by Western blot analysis. All animal care and work were in accordance with national and institutional guidelines and the Institutional Animal Care and Use Committee at the University of Pennsylvania.

Generation of BMCCs. Bone marrow-derived mast cells (BMCCs) were generated as previously described (20). Briefly, BM cells were obtained from the femurs and tibias of wild-type (WT) or mutant mice. BMCCs were generated by culturing BM cells in mast cell medium (MCM) (RPMI 1640, 15% fetal calf serum [FCS], 100 U/ml penicillin, 100 μg/ml streptomycin, 2.9 mg/ml glutamine, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 1× nonessential amino acids, 10 mM HEPES) containing interleukin 3 (IL-3) (10 ng/ml) and stem cell factor (SCF) (1.25 ng/ml) for 6 to 8 weeks with the medium replenished twice weekly. BMCCs were used when >95% of cells expressed high levels of FcεRI and c-Kit (CD117), as determined by flow cytometry. Cytokines and culture reagents were purchased from Peprotech (Rocky Hill, NJ) and Invitrogen (Carlsbad, CA), respectively.

**FcεRI-induced inflammatory mediator release.** To measure degranulation, BMCCs were allowed to rest overnight in MCM containing IL-3 (10 ng/ml) and IL-4 (10 ng/ml). The BMCCs were then incubated with 1 μg/ml anti-dinitrophenol (anti-DNP) IgE (clone SPE-7, Sigma-Aldrich, St. Louis, MO) for 2 h at 37°C, washed, and stimulated with various concentrations of dinitrophenol-conjugated human serum albumin (HSA-DNP, Sigma) for 1 h in Tyrode’s buffer (130 mM NaCl, 10 mM HEPES, 1 mM MgCl2, 5 mM KCl, 1.4 mM CaCl2, 5.6 mM glucose, 1 mg/ml bovine serum albumin [pH 7.4]). Supernatants were tested for β-hexosaminidase activity by incubating with 1 mM p-nitrophenyl-N-acetylβ-D-glucosamide (Sigma-Aldrich) dissolved in 0.1 M citrate buffer (pH 4.5) for 1 h at 37°C and terminating with 0.1 M Na2CO3·NaHCO3 buffer in 96-well flat-bottom plates. Absorbance at 405 nm was read with a plate reader. Total cellular β-hexosaminidase activity was quantified by lysing cells with 1% Triton X-100. Serial dilutions of a known quantity of lysed BMCCs were used as a standard to quantitatively determine degranulation (total activity/activity of the activated BMCCs)(total activity/activity of unstimulated BMCCs) > 100. To measure cytokine and chemokine production, BMCCs were allowed to rest overnight in MCM containing IL-3 (10 μg/ml), incubated with 1 μg/ml anti-DNP IgE for 2 h at 37°C, washed, and stimulated with various concentrations of HSA-DNP for 24 h in MCM. Supernatants were harvested and tested for the presence of IL-6 and monocyte chemotactic protein-1 (MCP-1) by enzyme-linked immunosorbent assay (ELISA) (BD Pharmingen, San Diego, CA) according to the manufacturer’s protocol.

**FcεRI-induced Ca2+ flux.** BMCCs were sensitized with 1 μg/ml anti-DNP IgE for 2 h at 37°C, washed, and resuspended at 1 × 107 cells/ml in Tyrode’s buffer containing 1 mM Probenecid (Sigma-Aldrich) and 3 μg/ml Indo-1 (Invitrogen). The cells were protected from light and incubated at 37°C for 30 min. Indo-1-loaded cells were washed three times and resuspended in Tyrode’s buffer (37°C) Tyrode’s buffer. In some experiments, the cells were resuspended in phosphate-buffered saline (PBS) containing EGTA (10 mM) instead of Tyrode’s buffer to remove extracellular Ca2+ immediately prior to activation. The cells were stimulated with HSA-DNP (100 ng/ml), and Ca2+ flux was measured by determining the ratio of fluorescence emitted at λ = 482/498 using an LSR flow cytometer (Becton Dickinson, Franklin Lakes, NJ). In some experiments, thapsigargin (1 μM) was used to inhibit endolysosomal reticulum Ca2+ ATPase and activate store-operated Ca2+ (SOC) channels. Baseline Ca2+ levels were measured for 30 s prior to the addition of HSA-DNP. The sample was collected for a total of 180 s, and ionomycin (1 μM) was added 30 s prior to the end of the assay. Data were analyzed using FlowJo software (TreeStar, Ashland, OR).

**Immunoprecipitation and Western blot analysis of mast cell lysates.** BMCCs were prewashed with anti-DNP IgE (1 μg/ml) for 2 h, washed, allowed to rest for 2 h, and stimulated with HSA-DNP (30 ng/ml) for indicated times. The cells were then lysed in 1% Igepal in Tris-buffered saline with protease/phosphatase inhibitors (protease inhibitor cocktail solution [Roche, Sigma], 1 mM sodium orthovanadate, 50 mM sodium fluoride, 50 mM sodium pyrophosphate, 0.2 mM dichloroaceticacid, and 1 mM benzamidine), and the proteins were resolved by SDS-PAGE (Bio-Rad Laboratories, Hercules, CA). The phosphorylation of PLCγ1 (Try783), PLCγ2 (Try1217), ERK1/2 (Thr202/Tyr204), SLP-76 (Try768), and c-Kit (CD117), as determined by flow cytometry. Total PLCγ1/p58 mitogen-activated protein kinase (MAPK), and SLP-76 were used as loading controls. All antibodies were purchased from Cell Signaling (Danvers, MA), except for the anti-phospho-SLP-76 (Tyr128) antibody, which was from eBioscience (San Diego, CA). For immunoprecipitations, BMCCs were prewashed with anti-DNP IgE (1 μg/ml) for 2 h, washed, allowed to rest for 2 h, and stimulated with HSA-DNP (30 ng/ml) for indicated times. The cells were then lysed and incubated for 30 min at 4°C with anti-mouse Ig TrueBlot Sepharose beads (Invitrogen) that were preincubated with anti-SLP-76 antibody (1.5 μg/50 μl of beads; eBioscience). The beads were washed extensively in lysis buffer (Tris-buffered saline with 1% Igepal, 1% Triton X, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 60 mM octyl-β-glucoside, and protease/phosphatase inhibitors), transferred to a separate tube, and boiled with loading buffer. The proteins were resolved by SDS-PAGE, and the presence of PLCγ1, SLP-76, and phosphotyrosine (pY; clone 4G10) was analyzed by Western blotting.
Retroviral transduction of BMMCs. BM cells were cultured in MCM with IL-3 (10 ng/ml), IL-6 (10 ng/ml), and SCF (50 ng/ml) at 37°C overnight. The BM cells were then centrifuged in 12-well plates containing 1 ml of MCM with Polybrene (4 μg/ml), IL-3, IL-6, SCF, and murine stem cell viral supernatant (MigR1) encoding either green fluorescent protein (GFP)-tagged SLP-76 (GFP-SLP-76), GFP-tagged SLP-76 GADS-binding mutant (SLP-76.G2), GFP-tagged SLP-76 SH2 domain mutant (SLP-76.RK), or LAT1/SLP-76 fusion protein (LAT1-SLP) followed by internal ribosome entry site (IRES)-GFP, or IRES-GFP alone for 90 min at 1,250 × g. The MigR1 constructs have been described previously (36). LAT1-SLP, which is a fusion protein between the first 35 amino acids of LAT1 and full-length SLP-76, and the SLP-76 mutants have been described previously (29, 31), WT, SLP-76ε BMMCs (Fig. 1A to C). However, a direct comparison of SLP-76ε−/− and LAT1ε−/− BMMCs revealed that SLP-76ε−/− BMMCs were significantly more defective than LAT1ε−/− BMMCs in both degranulation and MCP-1 production (Fig. 1A to C). Importantly, SLP-76ε−/− and LAT1ε−/− BMMCs degranulated and produced IL-6 and MCP-1. Each of these mast cell functions was dramatically decreased in both SLP-76ε−/− and LAT1ε−/− BMMCs (Fig. 1A to C). However, a direct comparison of SLP-76ε−/− and LAT1ε−/− BMMCs revealed that SLP-76ε−/− BMMCs were significantly more defective than LAT1ε−/− BMMCs in both degranulation and MCP-1 production (Fig. 1A to C). Importantly, SLP-76ε−/− and LAT1ε−/− BMMCs degranulated and produced MCP-1 to a similar extent when proximal signaling was bypassed by stimulation with a phorbol ester (data not shown). These data demonstrate that SLP-76ε−/− mast cells are functionally more defective than LAT1ε−/− mast cells.

Activation of PLCγ by SLP-76 and LAT1 leads to a subsequent rise in intracellular Ca2+ that is critical for mast cell function. To examine whether SLP-76ε−/− and LAT1ε−/− mast cells differed in activation of the PLCγ pathway, the phosphorylation of PLCγ was examined. Compared to WT BMMCs, the inducible phosphorylation of PLCγ1 and PLCγ2 was markedly but similarly diminished in SLP-76ε−/− and LAT1ε−/− BMMCs following FcεRI-mediated stimulation (Fig. 2A). However, the ability of SLP-76ε−/− and LAT1ε−/− BMMCs to mobilize intracellular Ca2+ following FcεRI-mediated activation appeared to differ. For the first 15 to 30 s following FcεRI activation, SLP-76ε−/− BMMCs exhibited a marked delay in Ca2+ flux, while the initial upstroke of Ca2+ flux was almost completely intact in LAT1ε−/− BMMCs. Despite these differences, intracellular Ca2+ levels of SLP-76ε−/− and LAT1ε−/− BMMCs eventually converged to a similarly depressed level compared to WT mast cells.

RESULTS

The function of SLP-76 is partially independent of LAT1 in mast cells. Models generated from T-cell studies predict that the recruitment of SLP-76 from the cytosol to the plasma membrane by phosphorylated LAT1 is critical for SLP-76 function. Thus, SLP-76−/− and LAT1−/− T cells are expected to elicit similar functional and biochemical defects. To test this notion in mast cells, BMMCs were generated from wild-type (WT) mice and mice lacking SLP-76 or LAT1. As described previously (29, 31), WT, SLP-76ε−/−, and LAT1ε−/− BMMCs were phenotypically similar and expressed equivalent levels of CD117 and FcεRI (data not shown). Upon stimulation through FcεRI, WT BMMCs exhibited robust degranulation and produced IL-6 and MCP-1. Each of these mast cell functions was dramatically decreased in both SLP-76ε−/− and LAT1ε−/− BMMCs (Fig. 1A to C). However, a direct comparison of SLP-76ε−/− and LAT1ε−/− BMMCs revealed that SLP-76ε−/− BMMCs were significantly more defective than LAT1ε−/− BMMCs in both degranulation and MCP-1 production (Fig. 1A to C). Importantly, SLP-76ε−/− and LAT1ε−/− BMMCs degranulated and produced MCP-1 to a similar extent when proximal signaling was bypassed by stimulation with a phorbol ester (data not shown). These data demonstrate that SLP-76ε−/− mast cells are functionally more defective than LAT1ε−/− mast cells.
showed functionally and biochemically distinct activation profiles after FcεRI stimulation, we questioned whether SLP-76 membrane recruitment and phosphorylation were dependent on LAT1 in mast cells. To measure SLP-76 phosphorylation in mast cells, an antibody that specifically recognizes the phosphorylated form of Y128 of SLP-76 was used. In addition, we immunoprecipitated SLP-76 and looked for all tyrosine phosphorylation of SLP-76, since at least two other tyrosines known to be phosphorylated (Y112 and Y145) contribute greatly to SLP-76 function. By using both methods, SLP-76 phosphorylation was similar in LAT1−/− BMMCs compared to WT BMMCs at all time points tested (Fig. 3A and B). Because SLP-76 phosphorylation was intact, we next sought to determine whether SLP-76 was recruited to signaling microclusters in LAT1−/− BMMCs following FcεRI engagement. Normal SLP-76 recruitment to membrane microclusters was observed in LAT1−/− BMMCs by fluorescence microscopy (Fig. 3C). These data suggest that activation of SLP-76 could occur independently of LAT1 in mast cells.

LAT2 is responsible for localization/phosphorylation of SLP-76 and residual function in LAT1−/− mast cells. In contrast to T cells, mast cells express another LAT1-like molecule known as LAT2. LAT2 is a membrane-bound adaptor molecule containing five tyrosines that are putative binding sites for Grb2 (4) and GADS (15), thereby making it potentially suitable for SLP-76 localization to the plasma membrane. To test whether LAT2 compensated for LAT1 deficiency in mast cells, BMMCs were generated from WT, LAT1−/−, LAT2−/−, and LAT1−/− LAT2−/− mice. The level of SLP-76 phosphorylation was similar among WT, LAT1−/−, and LAT2−/− BMMCs following FcεRI stimulation (Fig. 3A and B). However, in the absence of both LAT1 and LAT2, SLP-76 phosphorylation was markedly decreased (Fig. 3A and B). Similarly, membrane recruitment of SLP-76 was observed in WT, LAT1−/−, and LAT2−/− BMMCs but was severely diminished in LAT1−/− LAT2−/− BMMCs (Fig. 3C). Next, the function of LAT1−/− LAT2−/− BMMCs was compared to SLP-76−/− BMMCs. Although LAT1−/− BMMCs were more functional than SLP-76−/− BMMCs, LAT1−/− LAT2−/− and SLP-76−/− BMMCs were equally defective in degranulation and MCP-1 production (Fig. 3D and E). These data suggest that LAT2 is responsible for the localization and phosphorylation of SLP-76 and for the residual function in LAT1−/− mast cells. Of note, the increased degranulation response of the LAT2−/− BMMCs is consistent with previous reports demonstrating that LAT2−/− BMMCs are hyperfunctional due to an increased amount of LAT1 in the plasma membrane (23, 40).

To gain insight into the molecular mechanism by which LAT2 interacted with SLP-76, we tested the ability of two mutant SLP-76 molecules to be phosphorylated in BMMCs following FcεRI cross-linking. BMMCs were retrovirally transduced with either GFP-tagged forms of WT SLP-76, SLP-76 with a mutation of the GADS-binding domain (SLP-76.G2), or SLP-76 with a mutation in the SH2 domain (SLP-76.RK). Upon FcεRI activation, equal phosphorylation of both WT SLP-76 and SLP-76.RK was observed, suggesting that the SH2 domain of SLP-76 was not necessary for SLP-76 phosphorylation. In contrast, phosphorylation of SLP-76.G2 was severely diminished, suggesting that the GADS-binding domain of SLP-76 is critical for SLP-76 phosphorylation (Fig. 3F). Similarly, phosphorylation of SLP-76.G2 was not seen in LAT1−/− BMMCs (Fig. 3F), suggesting that LAT2 allowed SLP-76 phosphorylation to occur, potentially through a LAT2/GADS/SLP-76 interaction.
using our Western blot approach. Thus, to examine the effect of LAT1 and SLP-76 deficiency on very early PLCγ activation, we examined Ca\(^{2+}\) flux in mast cells in the absence of extracellular Ca\(^{2+}\). This restricts the source of Ca\(^{2+}\) to intracellular stores only and is a reflection of the amount of inositol trisphosphate (IP3) produced due to PLCγ activation. Upon chelation of extracellular Ca\(^{2+}\), we found that LAT1/−/− mast cells did display a rapid rise and then a decrease in intracellular Ca\(^{2+}\) levels (Fig. 4B). These data support the notion that LAT2 can support a rapid but transient activation of PLCγ.

We reasoned that the inability of LAT2 to sustain PLCγ activation might be due to the lack of a PLCγ-binding tyrosine in LAT2. The PLCγ-binding tyrosine of LAT1 has been shown to be crucial for the function of LAT1 (32), and thus, cooperative stabilization of PLCγ by LAT1 and SLP-76 may be important for prolonged PLCγ activation. LAT2 lacks this putative PLCγ-binding tyrosine motif (18) and therefore may not be able to assist SLP-76 in stabilizing PLCγ at the plasma membrane. To test this possibility, PLCγ binding to SLP-76 was measured in WT and LAT1/−/− BMMCs. Basal and FcεRI-induced binding of PLCγ to SLP-76 was greatly reduced in LAT1/−/− BMMCs compared to WT BMMCs (Fig. 4C), suggesting that LAT2 alone cannot stabilize the SLP-76/PLCγ interaction.

Localization of SLP-76 can be forced to the plasma membrane by fusing the transmembrane portion of LAT1 to full-length SLP-76 (LAT1-SLP). Expression of LAT1-SLP rescues the function of both SLP-76- and LAT1-deficient Jurkat T cells (3). This protein mimics the LAT2/SLP-76 interaction, since it allows for SLP-76 localization to the plasma membrane with-
Results are representative of at least two independent experiments. anti-DNP IgE, and stimulated with various concentrations of HSA-to the extracellular domain of LAT1 (LAT1-SLP), preincubated with rally transduced with vector alone (MIGR) or full-length SLP-76 fused

**FIG. 4.** Cooperation of SLP-76 and LAT1 is important for FcRI-mediated signaling and function. (A) WT, LAT1−/−, LAT1+/−, LAT2−/−, and SLP-76−/− BMMCs were preincubated with anti-DNP IgE (1 μg/ml) and monitored for elevations in intracellular Ca2+ by flow cytometry after stimulation in Tyrode’s buffer. (B) WT, LAT1−/−, and SLP-76−/− BMMCs were preincubated with anti-DNP IgE (1 μg/ml) and monitored for elevations in intracellular Ca2+ by flow cytometry after stimulation in PBS containing EGTA (10 mM). The arrows indicate the time when the stimulus (HSA-DNP or ionomycin) was added to the mast cells. (C) WT, LAT1−/−, and SLP-76−/− BMMCs were preincubated with anti-DNP IgE and stimulated with HSA-DNP (30 ng/ml) for the indicated time. Cell lysates were immunoprecipitated with anti-SLP-76 antibody and blotted for total SLP-76 and PLCγ1. (D) WT, SLP-76−/−, or LAT1−/− BMMCs were retrovirally transduced with vector alone (MIGR) or full-length SLP-76 fused to the extracellular domain of LAT1 (LAT1-SLP), preincubated with anti-DNP IgE, and stimulated with various concentrations of HSA-DNP. Cell-free culture supernatants were analyzed for degranulation. Results are representative of at least two independent experiments.

out cooperative binding of PLCγ. Since the LAT2/SLP-76 interaction was insufficient for full activation of mast cells, we reasoned that unlike Jurkat T cells, LAT1-SLP might not be able to rescue the defect afforded by LAT1 deficiency in mast cells. To test this notion, SLP-76−/− and LAT1−/− BMMCs were retrovirally transduced with LAT1-SLP and analyzed for FcRI-mediated degranulation responses. Expression of LAT1-SLP rescued the degranulation defect of SLP-76−/− BMMCs, but not LAT1−/− BMMCs (Fig. 4D). Thus, localization of SLP-76 to the plasma membrane is insufficient for full activation of mast cells in the absence of LAT1.

SLP-76 and LAT1 independently contribute to phosphorylation of ERK. Although SLP-76−/− mast cells are severely defective in FcεRI-mediated mast cell activation, some residual Ca2+ flux is still observed (Fig. 2A). Moreover, ERK phosphorylation is entirely intact in SLP-76−/− mast cells (41). LAT1 may direct Ca2+ flux and ERK phosphorylation independently of SLP-76 by localizing PLCγ and Grb2/SOS (SOS stands for son of sevenless), respectively. To test this notion, BMMCs from SLP-76−/− LAT1−/− mice were generated and compared to LAT1−/− and SLP-76−/− BMMCs. LAT1−/− and SLP-76−/− BMMCs displayed decreased Ca2+ flux upon FcεRI stimulation compared to WT BMMCs (Fig. 5A). SLP-76−/− LAT1−/− BMMCs exhibited a further decrease in Ca2+ flux (Fig. 5A), suggesting that LAT1 contributed to Ca2+ flux independently of SLP-76. Next, ERK phosphorylation was examined in FcεRI-stimulated BMMCs. Similar to previous observations (41, 47), ERK phosphorylation remained largely intact in SLP-76- and LAT1-deficient BMMCs compared to WT BMMCs (Fig. 5C). In contrast, ERK phosphorylation was markedly decreased in SLP-76−/− LAT1−/− BMMCs. Only one SLP-76−/− LAT1−/− mouse could be obtained for these experiments due to high perinatal lethality of these mice. Thus, to confirm these results, SLP-76−/− LAT1−/− BMMCs were also obtained by using LAT1−/− mice with conditionally deleted SLP-76 (SLP-76flox/flox). Similar results were obtained from experiments using these mast cells (Fig. 5B and D). Surprisingly, LAT1−/− LAT2−/− mast cells exhibited near-normal ERK phosphorylation after FcεRI cross-linking (Fig. 5E) despite the markedly decreased ability of these mast cells to localize and phosphorylate SLP-76. This suggests that only a small amount of SLP-76 phosphorylation might be necessary for ERK activation in mast cells. Together, these findings suggest that although SLP-76 and LAT1 depend on each other for many of their functions, SLP-76-independent LAT1-dependent and LAT1-independent SLP-76-dependent signals also contribute to FcεRI-mediated activation of mast cells.

**DISCUSSION**

We demonstrate herein that LAT1−/− BMMCs display milder functional and biochemical defects than SLP-76−/− BMMCs do. Moreover, localization and phosphorylation of SLP-76 in LAT1−/− BMMCs were largely normal, which were mediated by LAT2 in LAT1−/− mast cells. However, LAT2 failed to fully support LAT1-mediated signaling due to diminished stability of the SLP-76/PLCγ interaction. SLP-76 and LAT1 also independently contribute to mast cell activation, as SLP-76−/− LAT1−/− BMMCs showed a further decrease in Ca2+ flux and impaired ERK phosphorylation compared to SLP-76−/− or LAT1−/− BMMCs. Collectively, these data establish cooperative and independent roles for these adaptor molecules in their contribution to FcεRI-mediated mast cell activation (Fig. 6).

In contrast to the milder defects in degranulation and MCP-1 production by LAT1−/− BMMCs, IL-6 production was equally depressed in SLP-76- and LAT1-deficient BMMCs. While we do not know the exact mechanism that contributes to this finding, it is possible that the activation threshold for IL-6 production is higher than that of MCP-1 or degranulation. This notion is supported by a previous study demonstrating that strong signals from FcεRI preferentially lead to IL-6 production, while weaker signals lead to MCP-1 production (12).
Thus, the weak signal transduced by LAT1−/− BMMCs may be sufficient for some MCP-1 production, whereas it is insufficient for IL-6 production.

SLP-76 localization and phosphorylation were greatly diminished in LAT1−/− LAT2−/− BMMCs but intact in LAT1−/− BMMCs, suggesting that LAT2 is as efficient as LAT1 in drawing SLP-76 to the membrane. It is important to note, however, that the phosphorylation of SLP-76 was not completely lost in LAT1−/− BMMCs, suggesting that LAT2 is as efficient as LAT1 in drawing SLP-76 to the membrane. It is important to note, however, that the phosphorylation of SLP-76 was not completely lost in LAT1−/− BMMCs, suggesting that LAT2 is as efficient as LAT1 in drawing SLP-76 to the membrane. This occurs through the GADS-binding domain of SLP-76, implicating the involvement of GADS in this process. Three distinct molecular complexes involving PLCγ contribute to its activation: LAT1/SLP-76, LAT2/SLP-76, and LAT1 alone. Because LAT1, but not LAT2, cooperatively binds to PLCγ with SLP-76, LAT1/SLP-76/PLCγ contributes most to increasing intracellular Ca2+ levels. LAT1 and SLP-76 both cooperatively and independently lead to ERK phosphorylation. Thus, deletion of both LAT1 and SLP-76 is required for disruption of the ERK signaling pathway. SLP-76-independent LAT1-dependent ERK activation may involve localization of Grb2/SOS by LAT1. The upstream molecule(s) involved in LAT1/2-independent SLP-76 activation leading to ERK phosphorylation is unknown at this time.
SLP-76. However, it is clear that for optimal SLP-76 phosphorylation to occur, membrane localization through LAT1 or LAT2 is required.

The recruitment of SLP-76 to LAT2 likely brings SLP-76-bound PLCγ to the plasma membrane and may drive the quick upstroke in Ca\(^{2+}\) flux immediately following FcεRI stimulation. Indeed, an indirect association of LAT2 and PLCγ involving an unidentified cytosolic adaptor protein has been reported (16). Although LAT2 supports initial Ca\(^{2+}\) flux, it is insufficient to sustain Ca\(^{2+}\) flux at WT levels. Consistent with this observation, PLCγ phosphorylation is largely diminished in LAT1\(^{-/-}\) BMMCs, suggesting that the LAT2/SLP-76 interaction is insufficient for optimal PLCγ phosphorylation. This finding may be explained by the lack of the PLCγ-binding tyrosine in LAT2. Unlike LAT1, LAT2 cannot cooperatively bind to PLCγ with SLP-76, and hence, the localization of PLCγ can be sustained only temporally, which is reflected in the decreased association of PLCγ with SLP-76 in the presence of LAT2 alone. The levels of PLCγ phosphorylation in LAT1\(^{-/-}\) BMMCs and SLP-76\(^{-/-}\) BMMCs are indistinguishable 30 s after FcεRI stimulation, suggesting that PLCγ activation cannot be sustained in the absence of LAT1. Thus, despite having the ability to localize SLP-76, LAT2 differs from LAT1 in its ability to mediate FcεRI-mediated positive signals.

Although FcεRI-mediated signaling is severely defective in SLP-76\(^{-/-}\) mast cells, some biochemical signaling pathways are retained. For example, the phosphorylation of ERK is unaltered in SLP-76\(^{-/-}\) mast cells. ERK activation involves a cascade of phosphorylation events mediated by a series of kinases beginning with the activation of Ras GTPase. In mast cells, the activation of Ras can be mediated by at least two distinct guanine nucleotide exchange factors, RasGRP (8) and son of sevenless (SOS) (17). Activation of both factors potentially involves LAT1 and SLP-76, since RasGRP is activated by diacylglycerol (DAG)/Ca\(^{2+}\) following PLCγ activation and Grb2-associated SOS is localized by LAT1. However, the proximal signaling pathways leading to activation of Rac in mast cells have been unclear, as mast cells lacking either SLP-76 or LAT1 display intact phosphorylation of ERK (11, 41, 47). Because multiple signaling pathways contribute to Rac activation and the threshold for ERK phosphorylation is low, blockade of more than one pathway may be necessary to observe any reduction in ERK phosphorylation. Indeed, our data suggest that LAT1 and SLP-76 independently contribute to ERK activation and that ERK phosphorylation is decreased only when both SLP-76 and LAT1 are lacking in mast cells. The SLP-76-independent LAT1-dependent ERK phosphorylation is likely due to binding of Grb2/SOS to LAT1, which has been shown to occur independently of SLP-76 (42). Surprisingly, LAT1\(^{-/-}\)/LAT2\(^{-/-}\) mast cells exhibited near-normal ERK phosphorylation after FcεRI cross-linking, despite the decreased abilities of these mast cells to localize and phosphorylate SLP-76. This result suggests that LAT2/LAT1-independent SLP-76-dependent function also contributes to ERK phosphorylation.

Optimal PLCγ activation requires the cooperative stabilization of PLCγ by LAT1 and SLP-76. However, SLP-76 and LAT1 can also contribute independently to Ca\(^{2+}\) immobilization, as SLP-76\(^{-/-}\)/LAT1\(^{-/-}\) BMMCs exhibit a further decrease in Ca\(^{2+}\) flux compared to mast cells lacking either SLP-76 or LAT1. It appears that the PLCγ-binding tyrosine of LAT1 has some ability to localize PLCγ without SLP-76. Alternatively, it is possible that another SLP-76-like molecule compensates in the absence of SLP-76. Mast cells express the SLP-76-related protein cytokine-dependent hematopoietic cell linker (Clnk), which has the ability to localize PLCγ through its phosphorylated tyrosine. Although Clnk\(^{-/-}\) mast cells have been shown to degranulate normally compared to WT controls (38), a similar scenario to LAT2/LAT1 may exist where the positive signaling effects of Clnk may be apparent only in the absence of SLP-76. Thus, SLP-76\(^{-/-}\)/Clnk\(^{-/-}\) mast cells may show additional defects over SLP-76\(^{-/-}\) mast cells and phenocopy SLP-76\(^{-/-}\)/LAT1\(^{-/-}\) mast cells.

Not all signals downstream of FcεRI require SLP-76, LAT1, and LAT2. The phosphorylation of Akt is unaltered in SLP-76\(^{-/-}\) mast cells as well as SLP-76\(^{-/-}\)/LAT1\(^{-/-}\) mast cells (data not shown), suggesting that these adaptor molecules do not contribute to Akt activation. Akt activation likely occurs through an entirely distinct signaling pathway involving Fyn and the adaptor protein Gab2 (28). Accordingly, SLP-76\(^{-/-}\)/Fyn\(^{-/-}\) mast cells but not SLP-76\(^{-/-}\) mast cells demonstrate decreased Akt phosphorylation (21).

It is unclear what role LAT2 plays in FcεRI-mediated signaling in WT mast cells expressing LAT1. In initial studies, LAT2 was thought to be a negative regulator of mast cell activation, as LAT2\(^{-/-}\) mast cells displayed heightened activation compared to WT controls (40, 47); however, this effect was explained by LAT1 and LAT2 competing for sites in the plasma membrane and for phosphorylation by Syk. Nevertheless, expression of LAT2 would be expected to negatively impact mast cell activation, given that LAT2 is less effective than LAT1 in mediating a positive signal downstream of FcεRI. It is possible that the regulation of the LAT1/LAT2 ratio within mast cells plays a role in modulating mast cell activation. Decreased expression of LAT1 or increased LAT2 expression (decreased LAT1/LAT2 ratio) could make mast cells less responsive to FcεRI cross-linking stimuli. Such changes in the expression pattern of LAT1/LAT2 have been reported to occur in TCR-activated T cells (46) and cytokine-stimulated NK cells (6). Although resting T cells do not express LAT2, inducible LAT2 expression by activated T cells appears to negatively regulate their function, as aged LAT2\(^{-/-}\) mice develop a T-cell-mediated autoimmune syndrome (46). It is thus conceivable that similar regulation of LAT1/LAT2 ratios in mast cells could also alter their activation threshold.

In sum, we have demonstrated that redundancy of function exists between the related adaptor molecules LAT1 and LAT2 in the activation of SLP-76. Although SLP-76 and LAT1/LAT2 mainly exert their functions through cooperation, each of these molecules can also contribute individually to FcεRI-mediated positive signals. Further investigation is required to clarify the precise role of each of these adaptor molecules and to establish relevance to FcεRI-stimulated mast cell functions.

ACKNOWLEDGMENTS

We thank members of the Koretzky and Kambayashi laboratories for helpful discussions and Rebecca May, Kim Nichols, and Justina Stadanlick for careful reading of our manuscript. This work was supported by grants from the Sandler Program for Asthma Research and from the National Institutes of Health.
REFERENCES

1. Abraham, R. T., and A. Weiss. 2004. Jurkat T cells and development of the T-cell receptor signaling paradigm. Nat. Rev. Immunol. 4:301–308.

2. Baker, R. G., C. J. Hsu, D. Lee, M. S. Jordan, J. S. Maltzman, D. A. Hammer, T. Baumgart, and G. A. Koretzky. 2009. The adaptor protein SAP mediates “outside-in” integrin signaling and function in T cells. Mol. Biol. Cell. 20:5785–5798.

3. Boehr, N. J., J. J. Saaler, D. E. Bauer, J. L. Clements, S. M. Gheith, and G. A. Koretzky. 2000. Recruitment of SAP to the membrane of glycolipid-enriched membrane microdomains replaces the requirement for linker for activation of T cells (LAT) in T-cell receptor signaling. J. Exp. Med. 192:1047–1058.

4. Bredica, T., M. Imrich, P. Angelisova, N. Bredickova, O. Horvath, J. Spica, I. Hilgert, P. Luksova, P. Draber, P. Novak, N. Engels, J. Wiennands, L. Simeoni, J. Osterreicher, E. Aguado, M. Malissen, B. Schraven, and V. Horejš. 2002. Normal T-cell activation (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling. J. Exp. Med. 196:1617–1626.

5. Bubeck Wardenburg, J., C. Fu, J. K. Jackson, H. Fltow, S. E. Wilkinson, D. H. Williams, R. Johnson, G. Kong, A. C. Chan, and F. P. Findell. 1996. Phosphorylation of SAP by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J. Biol. Chem. 271:19641–19644.

6. Chiesa, S., M. Mingueuene, N. Fuseri, B. Malissen, D. H. Rauert, M. Malissen, E. Evier, and E. Tomasselli. 2006. Multiplicity and plasticity of natural killer cell signaling pathways. Blood 107:2364–2372.

7. Clements, J. L., S. E. Ross-Barta, L. T. Tygett, T. J. Waldschmidt, and G. A. Koretzky. 1998. SAP expression is restricted to hemopoietic cells of monocoyte, granulocyte, and T lymphocyte lineage and is regulated during T-cell development and activation. J. Biol. Chem. 273:3880–3889.

8. Ebinu, J. O., Y. Liu, S. Koonpaew, O. Granillo, and W. Zhang. 2002. Three membrane-distal tyrosines in the adaptor protein NTAL/LAB. J. Biol. Chem. 277:2395–2406.

9. El-Hillal, O., T. Kurosaki, H. Yamamura, J. P. Kinet, and A. M. Scharenberg. 1999. Lat or Ntol/Lab/LAT2. Immunity 11:1453–1465.

10. Ebinu, J. O., S. L. Stang, C. Teixeira, D. A. Bottorff, J. Hooton, P. M. Metcalfe, and A. Oliveira-Dos-Santos. 2007. Preferential signaling and induction of allergy-promoting lymphokines upon aggregation of the high affinity IgE receptor. J. Immunol. 178:8080–8089.

11. Ebinu, J. O., J. R. Tinkle, K. Volna, P. Lebduska, L. Draberova, S. Simova, P. Heneberg, M. Boubelik, M. A. Oliveira-Dos-Santos, L. Barra, S. Spiegel, J. M. Penninger, and J. Horejš. 2003. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 21:81–105.

12. El-Hillal, O., T. Kurosaki, H. Yamamura, J. P. Kinet, and A. M. Scharenberg. 1999. Lat or Ntol/Lab/LAT2. Immunity 11:1453–1465.

13. Ebinu, J. O., C. Oliveira-Dos-Santos, L. Barra, S. Spiegel, J. M. Penninger, and J. Horejš. 2003. Preferential signaling and induction of allergy-promoting lymphokines upon aggregation of the high affinity IgE receptor on mast cells. J. Exp. Med. 197:1443–1456.

14. Gould, H. J., and B. J. Sutton. 2008. IgE in allergy and asthma today. Nat. Rev. Immunol. 8:205–217.

15. Hines, C. 2002. The role of LAT in T-cell function. Immunol. Allergy. In press:149–160.

16. Ikawi, S., I. T. R. Martin, J. M. Lu-Kuo, H. R. Katz, H. C. Oettgen, and R. S. Geha. 1999. SAP: the high-affinity IgE receptor in mast cells. J. Clin. Invest. 103:1737–1743.

17. Itoh, T., J. P. Kinet. 1999. Signalling through the high-affinity IgE receptor Fc epsilon RI. Nature 402:824–830.

18. Utting, O., B. J. Sedgmen, T. H. Watts, X. Shi, R. Rottapel, A. Iulianella, D. Lohnes, and A. Veillette. 2004. Immune functions in mice lacking Clanin, an SAP-related adaptor expressed in a subset of immune cells. Mol. Cell. Biol. 24:6067–6075.

19. Vig, M., and J. P. Kinet. 2007. The long and arduous road to CRAC. Cell 129:155–162.

20. Volna, P., L. Lebduska, S. Simova, P. Heneberg, M. Boubelik, V. Bugajev, B. Malissen, B. S. Wilson, V. Horejši, M. Malissen, and D. Drabek. 2004. Negative regulation of mast cell signaling and function by the adaptor protein Clnk. J. Biol. Chem. 279:10101–10110.

21. Wu, J. N., M. S. Jordan, M. A. Silverman, E. J. O'Shea, and G. A. Koretzky. 2004. Differential requirement for adapter proteins Src homology 2 domain-containing leukocyte phosphoprotein of 76 kDa and degradation-promoting adaptor protein in Fc epsilon RI signaling and mast cell function. J. Immunol. 172:6768–6774.

22. Yablonski, D., M. R. Kuhne, T. Kadlec, and A. Weiss. 1998. Uncoupling of nonreceptor tyrosine kinases from PLC-gamma1 in an SAP-deficient T cell. Science 281:1413–1418.

23. Zhang, W., J. Sloan-Lancaster, J. Kitchen, R. P. Tribe, and L. E. Samelson. 1998. LAT1: the ZAP-70-dependent protein kinase signaling pathway through SOS and Grb2. J. Biol. Chem. 273:16268–16272.

24. Janssen, E. M., Z. Braven, and W. Zhang. 2004. Linker for activation of B cells: a functional equivalent of a mutual linker for activation of T cells deficient in phospholipase C-gamma1 binding. J. Immunol. 172:6810–6819.

25. Jouvin, M. H., M. Adamczewska, R. Numerof, O. Letourneur, A. Valle, and J. P. Kinet. 1994. Differential control of the protein kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J. Biol. Chem. 269:5918–5925.

26. Kambayashi, T., J. D. Baranski, R. G. Baker, T. Zou, E. J. Allenspach, J. E. Sheward, P. L. Jones, and G. A. Koretzky. 2008. Insect involvement of allergen-captured mast cells in antigen presentation. Blood 111:1498–1496.

27. Kambayashi, T., D. F. Larosa, M. A. Silverman, and G. A. Koretzky. 2009. Cooperation of adapter molecules in proximal signaling cascades during allergic inflammation. Immunol. Rev. 223:99–114.

28. Kettner, A. V., P. Vinicius, L. Kumar, H. Falet, J. S. Lee, R. Mulligan, and R. S. Geha. 2003. Structural requirements of SAP in signaling via the high-affinity immunoglobulin E receptor (Fc epsilon RI) in mast cells. Mol. Cell. Biol. 23:2290–2302.

29. Koonpaew, S., E. Janssen, M. Zhu, and W. Zhang. 2004. The importance of three membrane-distal tyrosines in the adaptor protein NTAL/LAB. J. Biol. Chem. 279:11229–11235.

30. Liu, S. K., N. Fang, G. A. Koretzky, and C. J. McDade. 1999. The hematopoietic-specific adaptor protein genes functions in T-cell signaling via interactions with the SAP-LAT1 adaptors. Curr. Biol. 9:675–7.